Drugs / HMBD-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05082610 | Feb 2022 → Nov 2024 | metastatic malignant neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma | Hummingbird Bioscience | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2022-11-07 | Hummingbird Bioscience | Results Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting hummingbirdbioscience.com ↗
The second poster shares preclinical data demonstrating that VISTA blockade with HMBD-002 reprograms tumor-associated macrophages to an inflammatory phenotype and promotes cytotoxic T-cell response. |
| 2022-02-09 | Hummingbird Bioscience | Results Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers hummingbirdbioscience.com ↗ |
| 2021-09-13 | Hummingbird Bioscience | Regulatory Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors hummingbirdbioscience.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has approved the initiation of a Phase 1 clinical trial of HMBD-002, Hummingbird’s anti-VISTA neutralizing antibody. |
| 2021-05-31 | Hummingbird Bioscience | Results Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society Of Clinical Oncology (ASCO) 2021 Annual Meeting hummingbirdbioscience.com ↗
The abstract reports pre-clinical studies that demonstrate HMBD-002’s ability to induce an effective anti-tumor immune response, both as a monotherapy and in combination with the checkpoint inhibitor pembrolizumab in multiple syngeneic and humanized xenograft models. |
| 2018-11-05 | Hummingbird Bioscience | Results Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting hummingbirdbioscience.com ↗
In tumor models, treatment with HMBD-002-V4 potently inhibited the growth of a variety of MDSC-high tumors without depletion of VISTA expressing cells. |
| 2018-04-10 | Hummingbird Bioscience | Results Hummingbird Bioscience to present data on HMBD-002-V4 at the American Association for Cancer Research (AACR) 2018 Annual Meeting hummingbirdbioscience.com ↗
Treatment with HMBD-002-V4 in combination with anti-PD(L)1 therapy counteracts the expansion of MDSCs and remodels the immunosuppressive tumor microenvironment towards a pro-inflammatory environment, resulting in potent inhibition of tumor growth in a variety of syngeneic murine cancer models with MDSC infiltration. |
All press releases naming this drug 10 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMBD-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05082610 ↗ |
| Known as | HMBD-002-V4C26 | “A Phase 1 Study of HMBD-002-V4C26 (HMBD-002), a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Malignancies” NCT05082610 ↗ |
| Modality | Monoclonal antibody | “IgG4 monoclonal antibody (mAb) targeting the V-domain immunoglobulin suppressor of T cell activation (VISTA) receptor.” NCT05082610 ↗ |
| Route | Intravenous | “HMBD-002 administered as a 60-minute IV infusion” NCT05082610 ↗ |